1. Home
  2. ELA vs ACRS Comparison

ELA vs ACRS Comparison

Compare ELA & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELA
  • ACRS
  • Stock Information
  • Founded
  • ELA 1965
  • ACRS 2012
  • Country
  • ELA United States
  • ACRS United States
  • Employees
  • ELA N/A
  • ACRS N/A
  • Industry
  • ELA Consumer Specialties
  • ACRS Biotechnology: Pharmaceutical Preparations
  • Sector
  • ELA Consumer Discretionary
  • ACRS Health Care
  • Exchange
  • ELA Nasdaq
  • ACRS Nasdaq
  • Market Cap
  • ELA 156.2M
  • ACRS 165.7M
  • IPO Year
  • ELA N/A
  • ACRS 2015
  • Fundamental
  • Price
  • ELA $6.04
  • ACRS $1.59
  • Analyst Decision
  • ELA Strong Buy
  • ACRS Strong Buy
  • Analyst Count
  • ELA 1
  • ACRS 9
  • Target Price
  • ELA $9.00
  • ACRS $9.25
  • AVG Volume (30 Days)
  • ELA 66.1K
  • ACRS 1.3M
  • Earning Date
  • ELA 08-06-2025
  • ACRS 08-06-2025
  • Dividend Yield
  • ELA N/A
  • ACRS N/A
  • EPS Growth
  • ELA 15.15
  • ACRS N/A
  • EPS
  • ELA 0.28
  • ACRS N/A
  • Revenue
  • ELA $188,774,278.00
  • ACRS $17,777,000.00
  • Revenue This Year
  • ELA $7.61
  • ACRS N/A
  • Revenue Next Year
  • ELA $6.27
  • ACRS $11.77
  • P/E Ratio
  • ELA $22.80
  • ACRS N/A
  • Revenue Growth
  • ELA 14.19
  • ACRS N/A
  • 52 Week Low
  • ELA $4.20
  • ACRS $1.05
  • 52 Week High
  • ELA $7.88
  • ACRS $5.17
  • Technical
  • Relative Strength Index (RSI)
  • ELA 50.27
  • ACRS 59.88
  • Support Level
  • ELA $5.97
  • ACRS $1.44
  • Resistance Level
  • ELA $6.35
  • ACRS $1.52
  • Average True Range (ATR)
  • ELA 0.25
  • ACRS 0.10
  • MACD
  • ELA 0.04
  • ACRS 0.00
  • Stochastic Oscillator
  • ELA 53.73
  • ACRS 79.17

About ELA Envela Corporation

Envela Corp is a provider of recycling and re-commerce services at the forefront of the circular economy. These include re-commercializing luxury hard assets, consumer electronics and IT equipment; and end-of-life recycling solutions. It operates through two segments, Consumer, and Commercial Services. The Consumer segment which generates key revenue for the company predominantly buys to resell or recycle luxury hard assets like jewelry, diamonds, gemstones, fine watches, rare coins and related collectibles, precious-metal bullion products, gold, silver, and other precious metals. The Commercial Services segment provides asset-disposition solutions to government agencies, middle-market firms, corporations, and other organizations.

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Share on Social Networks: